A potential of serum anti-C1P IgG antibodies as biomarkers in differential diagnosis of relapsing-remitting multiple sclerosis

Why this research matters to patients and families

Multiple sclerosis (MS) is a lifelong disease in which the body’s own immune system attacks the brain and spinal cord. Doctors still struggle to tell MS apart from other neurological illnesses in the early stages, and there is no simple blood test that confirms the diagnosis. This study explores whether certain antibodies in the blood that recognize fatty molecules from nerve insulation could serve as convenient markers to help distinguish a common form of MS from other brain and nerve disorders.

A closer look at MS and nerve‑coat fats

Nerve fibers in the brain and spinal cord are wrapped in a fatty coating called myelin, which helps electrical signals travel quickly and reliably. In MS, the immune system attacks this coating, causing inflammation and gradual damage to nerve fibers. The fats that make up myelin, known as sphingolipids, do more than form structure: they also act as signaling molecules that can either fan the flames of inflammation or help calm it down. Earlier work from the same research team showed that one group of these fats, called ceramides, is altered in MS brain tissue and spinal fluid, and that patients often carry antibodies against ceramides in their blood and spinal fluid. This suggested that breakdown products of myelin might become targets for the immune system.

A special fat called C1P and its antibodies

The new study focuses on ceramide‑1‑phosphate (C1P), a modified form of ceramide that can promote or dampen inflammation depending on the context. The researchers asked whether people with relapsing–remitting MS, the most common early form of the disease, have a distinctive pattern of antibodies that recognize different “subtypes” of C1P. These subtypes differ in the length and saturation of their fatty side chains, characteristics that influence where they reside in the brain and how they behave. By measuring antibodies against five C1P subtypes in blood samples, the team hoped to see whether any combination of these responses could serve as a fingerprint of MS, and whether this fingerprint related to how disabled a person was or how long they had been sick.

How the study was done

The researchers collected blood from 39 people with relapsing–remitting MS, 26 patients with other neurological diseases such as inflammatory neuropathies, strokes, or hydrocephalus, and 12 healthy volunteers. They purified the main class of antibodies, called IgG, from each sample and tested how strongly these antibodies bound to each of the five C1P subtypes using an established plate‑based assay. They then compared the results between groups and used statistical tools commonly applied to medical tests—such as receiver operating characteristic (ROC) curves and clustering methods—to see how well various antibody patterns could separate MS from the other groups.

What the researchers discovered

People with MS showed clear differences in their anti‑C1P antibody patterns compared with both healthy volunteers and patients with other neurological diseases. Compared with healthy subjects, MS patients had higher levels of antibodies against two subtypes, labeled C18:0‑C1P and C24:1‑C1P. When the team examined how well these measures behaved like diagnostic tests, both showed moderate ability to distinguish MS from health. When MS patients were compared to the mixed group of other neurological diseases, two different subtypes stood out: antibodies against C16:0‑C1P and C24:0‑C1P were consistently lower in MS, and these measures—especially those against C24:0‑C1P—offered good separation between the groups. By combining several antibody measures and applying cluster analysis, the researchers could group most MS patients apart from healthy and non‑MS neurological cases, suggesting that a panel of antibody responses performs better than any single value alone.

What these patterns mean for disease activity

Interestingly, the levels of anti‑C1P antibodies in MS did not track with how long a person had been ill, how disabled they were, or whether they were in a flare‑up or a quiet phase of the disease at the time of blood draw. This implies that the antibodies are more useful as markers that MS is present, and that it differs biologically from other neurological problems, rather than as a simple gauge of disease severity or short‑term activity. The authors argue that these antibodies likely arise as a secondary response to ongoing inflammation and disturbed fat metabolism in the brain, rather than being the main drivers of damage themselves.

What this could mean for future diagnosis

For people facing early, uncertain neurological symptoms, a blood test that helps distinguish MS from look‑alike conditions would be highly valuable. This study provides early evidence that antibodies against specific C1P subtypes could become part of such a test, especially when several of them are considered together. While the work needs confirmation in larger and more diverse patient groups—and must be paired with spinal fluid studies—it supports the idea that subtle changes in the immune response to nerve‑coat fats carry important clues. In the long run, understanding these lipid‑directed antibodies may not only sharpen diagnosis but also open new windows on how inflammation and nerve damage are intertwined in MS.

Citation: Chojdak-Lukasiewicz, J., Jakubiak-Augustyn, A., Szulc, Z.M. et al. A potential of serum anti-C1P IgG antibodies as biomarkers in differential diagnosis of relapsing-remitting multiple sclerosis. Sci Rep 16, 9437 (2026). https://doi.org/10.1038/s41598-026-43823-y

Keywords: multiple sclerosis, autoantibodies, lipids, biomarkers, neuroinflammation